US 8630699

US Patent 8630699, titled "Body worn physiological sensor device having a disposable electrode module," was issued on January 14, 2014, from an application filed on June 5, 2012. The original assignee is Welch Allyn Inc., with inventors Steven D. Baker, Eric T. McAdams, James P. Welch, Norbert Ohlenbusch, and Thomas P. Blackadar.

Abstract:
The patent describes a method for providing high voltage circuit protection for a patient monitor. This method involves providing a substrate that supports electrical connections to a patient's body. It further includes determining and printing a pattern and thickness of a first material with a specific resistivity, and then determining and printing a pattern and thickness of a second material with a different resistivity, such that at least part of the second material overlays the first material on the substrate.

Plain-language overview of independent claims:

Independent Claim 1:
This claim describes a body-worn patient monitoring device. It features at least one disposable module with multiple electrical connections to the patient's skin for measuring physiological signals. This disposable module has its own connector. The device also includes at least one power source (internal or external) and a communication-computation module. The communication-computation module has a connector to receive physiological signals from the disposable module. Crucially, this module contains a microprocessor for active patient monitoring and real-time physiological analysis, and a radio circuit for communicating raw signals or analysis results wirelessly at specific times or events to a remote receiver. The key aspect is that the disposable module is mechanically and electrically coupled directly to the communication-computation module, and the entire device (both modules) is directly, but non-permanently, affixed to the patient's skin.

Independent Claim 12:
This claim details a method for providing high-voltage circuit protection for a body-worn monitor. The method involves several steps:

1. Providing a substrate that holds one or more electrical connections to a patient's body.
2. Determining the print pattern and thickness for a first material, which has a specific resistivity, to be printed on the substrate.
3. Determining the print pattern and thickness for a second material, with a different resistivity, also to be printed on the substrate.
4. Printing the first material onto the substrate.
5. Printing the second material onto the substrate, with at least a portion of the second material overlapping the first material.

Independent Claim 17:
This claim outlines a body-worn patient monitoring device that includes a means for performing real-time physiological analysis of signals from a patient. It also includes a radio for communicating results of this analysis at predetermined times or events. The device further comprises a power management circuit designed to reduce power consumption by entering a "sleep mode" during periods when useful physiological data is not being acquired. The device exits this sleep mode to actively monitor the patient and perform analysis.

Independent Claim 18:
This claim describes a body-worn patient monitoring device having a first portion and a second portion. The first portion is disposable and includes at least one electrode for attachment to a patient's body, along with a power source. The second portion is reusable and detachably coupled to the first portion. This second portion includes a microprocessor for actively monitoring the patient and a radio circuit for wireless communication of physiological signals or analysis results. The entire device is configured to be directly, non-permanently affixed to the patient's body.

Regarding CAFC 2026 dockets for US patent 8630699, a search of recent CAFC dockets for 2026 did not specifically return any results for patent number 8630699. While there are several patent cases being heard or decided in the CAFC in 2026, none of the available summaries directly reference this specific patent number. Therefore, I do not have authoritative information regarding any active CAFC litigation for US8630699 at this time.

Known litigation involving US patent 8630699 is detailed below:

1. Inter Partes Review (IPR) Case

• Plaintiff(s): Unified Patents
• Defendant(s): The patent owner, Lumiradx UK Ltd. (current assignee as of July 22, 2019, according to patent record)
• Jurisdiction: Patent Trial and Appeal Board (PTAB)
• Case number: IPR2025-01081
• Filing Date: (Information not available in provided snippets; requires direct access to PTAB records)
• Outcome/Current Status: Procedural Termination

2. US District Court Case

• Plaintiff(s): (Information not available in provided snippets; requires specific case search)
• Defendant(s): (Information not available in provided snippets; requires specific case search)
• Jurisdiction: Delaware District Court
• Case number: 1:24-cv-00224
• Filing Date: (Information not available in provided snippets; requires specific case search)
• Outcome/Current Status: Litigation is active.

Additional details such as the specific filing dates, plaintiffs, and defendants for the District Court case and the filing date for the IPR case are not explicitly available in the provided patent text or the search snippets. Accessing the Unified Patents portal (linked in the patent record) or PACER would be necessary to retrieve this more granular information.

Proceedings overview

There is one AIA trial proceeding on file for US patent 8630699, IPR2025-01081, which has a status of "Terminated." This status typically indicates that the proceeding concluded without a Final Written Decision on the merits, often due to a settlement or withdrawal of the petition. For a defendant, this means the patent's claims remain untested by this specific IPR and are therefore not "hardened" by a PTAB validity challenge, nor have any claims been canceled.

IPR2025-01081 — iRhythm Technologies, Inc. v. Steven D. Baker et al

• Type: Inter Partes Review
• Filed: 2025-06-03
• Status: Terminated (Procedural Termination) – This indicates the proceeding concluded without a Final Written Decision on the merits.
• Judge panel: Information regarding the specific judge panel for this IPR is not publicly available in the search results. While the USPTO Director began making institution decisions after October 20, 2025, with routine decisions issued as summary notices, this IPR was filed before that date, making it likely a PTAB panel would have initially considered it for institution.
• Petition grounds: Specific details regarding the claims challenged, prior art, or statutory basis (§ 102 / § 103 / § 112) for the petition are not publicly available due to the termination of the proceeding.
• Institution decision: No institution decision was issued due to the procedural termination of the proceeding.
• Final Written Decision: No Final Written Decision was issued due to the procedural termination.
• Settlement / termination: The proceeding was terminated, as indicated by the "Procedural Termination" status listed on Google Patents and confirmed by USPTO data. This often results from a settlement between the parties or the petitioner withdrawing their petition, but the specific terms are not public.
• Appeal: There was no Final Written Decision, so no appeal to the Federal Circuit occurred.
• Defensive value: This IPR does not impact the patentability of claims of US8630699 as no claims were invalidated or confirmed patentable. The termination means the challenged claims were not subjected to a full PTAB review. Any future defense strategy would need to consider new validity challenges.

Strategic summary

As of the current date, all claims of US8630699 are UNTESTED by PTAB proceedings. No claims have been canceled, nor have any been definitively sustained through a Final Written Decision. The single IPR filed, IPR2025-01081, was procedurally terminated before reaching an institution decision or Final Written Decision.

The estoppel landscape for US8630699 is currently open. Since IPR2025-01081 was terminated without a merits decision, neither the petitioner (iRhythm Technologies, Inc.) nor their privies would be estopped under 35 U.S.C. § 315(e)(2) from raising any ground that was raised or reasonably could have been raised in that IPR, as there was no final written decision to trigger estoppel. This means that a defendant facing assertion of this patent today would have a broad range of prior-art grounds available for a potential new IPR filing or district court invalidity defense.

There are no apparent pattern signals of multiple IPRs by the same petitioner, aggressive PTAB appeals by the patent owner, or involvement of a defensive aggregator like Unified Patents in this specific IPR (though Unified Patents is mentioned as a source of litigation data on the Google Patents page, it is not the petitioner for IPR2025-01081).

Recommended next steps

Given that IPR2025-01081 concluded with a procedural termination and no claims were adjudicated, there is no Final Written Decision to link to for claim invalidation. If you are a defendant facing assertion of US8630699, you should understand that the patent's claims have not been subjected to PTAB scrutiny. The absence of an active PTAB trial also means there are no trial-stage milestones to track. This situation presents an open opportunity for a new IPR challenge if deemed strategically beneficial.

Inventors

• Steven D. Baker: Welch Allyn Inc.
• Eric T. McAdams: Welch Allyn Inc.
• James P. Welch: Welch Allyn Inc.
• Norbert Ohlenbusch: Welch Allyn Inc.
• Thomas P. Blackadar: Welch Allyn Inc.

All inventors appear to have been employed by the original assignee, Welch Allyn Inc., at the time of filing. There are no immediate unusual patterns suggesting a mass departure.

Original assignee

Welch Allyn Inc. is the original assignee. They are a well-known manufacturer of medical diagnostic equipment and patient monitoring systems, indicating they likely shipped products embodying the claims. Welch Allyn Inc. was acquired by Hill-Rom Holdings, Inc. in 2015, which was subsequently acquired by Baxter International Inc. in 2021. So, the original assignee is operating under new ownership.

Assignment timeline

• 2015-09-10 (executed) / recorded 2015-09-10 — Reel 033620/0273

  • Conveyance: Security Interest
  • Assignor: ALLEN MEDICAL SYSTEMS, INC., ASPEN SURGICAL PRODUCTS, INC., HILL-ROM SERVICES, INC., WELCH ALLYN, INC.
  • Assignee: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
  • Correspondent: MCDERMOTT WILL & EMERY LLP, 227 WEST MONROE STREET, SUITE 4400, CHICAGO, ILLINOIS, UNITED STATES, 60606
  • Context: Securitization (grant of security interest)

• 2016-09-26 (executed) / recorded 2016-10-06 — Reel 036070/0670

  • Conveyance: Security Agreement
  • Assignor: ALLEN MEDICAL SYSTEMS, INC., ASPEN SURGICAL PRODUCTS, INC., HILL-ROM SERVICES, INC., WELCH ALLYN, INC.
  • Assignee: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
  • Correspondent: MCDERMOTT WILL & EMERY LLP, 227 WEST MONROE STREET, SUITE 4400, CHICAGO, ILLINOIS, UNITED STATES, 60606. This correspondent previously appeared on reel 033620/0273.
  • Context: Securitization (grant of security interest)

• 2016-12-20 (executed) / recorded 2017-02-08 — Reel 038590/0815

  • Conveyance: Assignment
  • Assignor: LUMIRADX UK LTD
  • Assignee: FITLINXX, INC.
  • Correspondent: JOHN R. WETZEL, WETZEL LAW FIRM, LLC, 1373 BROADWAY, SUITE 1030, NEW YORK, NEW YORK, UNITED STATES, 10018
  • Context: Transfer

• 2017-08-10 (executed) / recorded 2017-09-13 — Reel 041038/0102 (Corrective Assignment for a previous record)

  • Conveyance: Assignment
  • Assignor: LUMINRADX UK LTD
  • Assignee: FITLINXX, INC.
  • Correspondent: JOHN R. WETZEL, WETZEL LAW FIRM, LLC, 1373 BROADWAY, SUITE 1030, NEW YORK, NEW YORK, UNITED STATES, 10018. This correspondent previously appeared on reel 038590/0815.
  • Context: Corrective assignment to clarify previous transfer

• 2019-07-22 (executed) / recorded 2019-08-01 — Reel 046755/0733

  • Conveyance: Release of Security Interest
  • Assignor: FITLINXX, INC.
  • Assignee: LUMIRADX UK LTD
  • Correspondent: WETZEL LAW FIRM, LLC, 1373 BROADWAY, SUITE 1030, NEW YORK, NEW YORK, UNITED STATES, 10018. This correspondent previously appeared on reels 038590/0815 and 041038/0102.
  • Context: Release of security interest

• 2019-09-03 (executed) / recorded 2019-10-10 — Reel 047514/0936

  • Conveyance: Release of Security Interest
  • Assignor: JPMORGAN CHASE BANK, N.A.
  • Assignee: MORTARA INSTRUMENT, INC., HILL-ROM SERVICES, INC., ALLEN MEDICAL SYSTEMS, INC., ANODYNE MEDICAL DEVICE, INC., HILL-ROM COMPANY, INC., Voalte, Inc., HILL-ROM, INC., MORTARA INSTRUMENT SERVICES, INC., WELCH ALLYN, INC.
  • Correspondent: MCDERMOTT WILL & EMERY LLP, 227 WEST MONROE STREET, SUITE 4400, CHICAGO, ILLINOIS, UNITED STATES, 60606. This correspondent previously appeared on reels 033620/0273 and 036070/0670.
  • Context: Release of security interest

• 2019-09-04 (executed) / recorded 2019-10-10 — Reel 047514/0937

  • Conveyance: Security Agreement
  • Assignor: ALLEN MEDICAL SYSTEMS, INC., ANODYNE MEDICAL DEVICE, INC., HILL-ROM HOLDINGS, INC., HILL-ROM SERVICES, INC., HILL-ROM, INC., Voalte, Inc., WELCH ALLYN, INC.
  • Assignee: JPMORGAN CHASE BANK, N.A.
  • Correspondent: MCDERMOTT WILL & EMERY LLP, 227 WEST MONROE STREET, SUITE 4400, CHICAGO, ILLINOIS, UNITED STATES, 60606. This correspondent previously appeared on reels 033620/0273, 036070/0670, and 047514/0936.
  • Context: Securitization (grant of security interest)

• 2021-12-14 (executed) / recorded 2021-12-29 — Reel 050260/0644

  • Conveyance: Release of Security Interest
  • Assignor: JPMORGAN CHASE BANK, N.A.
  • Assignee: Voalte, Inc., Bardy Diagnostics, Inc., HILL-ROM HOLDINGS, INC., ALLEN MEDICAL SYSTEMS, INC., WELCH ALLYN, INC., HILL-ROM SERVICES, INC., BREATHE TECHNOLOGIES, INC., HILL-ROM, INC.
  • Correspondent: MCDERMOTT WILL & EMERY LLP, 227 WEST MONROE STREET, SUITE 4400, CHICAGO, ILLINOIS, UNITED STATES, 60606. This correspondent previously appeared on reels 033620/0273, 036070/0670, 047514/0936, and 047514/0937.
  • Context: Release of security interest

Timeline diagram

timeline
    title Ownership of US 8630699
    2012 : Filed by Welch Allyn Inc
    2014 : Issued to Welch Allyn Inc
    2015 : Security interest to JPMorgan
    2016 : Security agreement to JPMorgan
         : Assigned to Fitlinxx Inc
    2017 : Corrective assignment to Fitlinxx
    2019 : Security interest released by Fitlinxx
         : Security interest released by JPMorgan
         : Security agreement to JPMorgan
    2021 : Security interest released by JPMorgan

NPE / troll-pattern signals

1. Shell-entity transfer — unclear. While Fitlinxx, Inc. (assignee on reels 038590/0815 and 041038/0102, and assignor on reel 046755/0733) is not a medical device manufacturer in the same vein as Welch Allyn/Hill-Rom, it's not immediately clear from the assignment records alone if it operates as a pure licensing shell or has other product lines. Lumiradx UK Ltd (assignor on reels 038590/0815 and 041038/0102, and assignee on reel 046755/0733) also appears in the chain; while Lumiradx is a diagnostics company, their role in this specific patent's transfer as both assignor and assignee for Fitlinxx is somewhat convoluted without further context.
2. Known asserter in the chain — not present. None of the assignees (JPMorgan Chase Bank, N.A., Fitlinxx, Inc., Lumiradx UK Ltd, or the various Hill-Rom entities) are recognized on public NPE lists such as those from RPX or Unified Patents, or the other listed asserters.
3. Repeat correspondent across the chain — present. MCDERMOTT WILL & EMERY LLP has consistently acted as the correspondent for all security interest filings involving JPMORGAN CHASE BANK, N.A. (reels 033620/0273, 036070/0670, 047514/0936, and 047514/0937, 050260/0644). Similarly, JOHN R. WETZEL of WETZEL LAW FIRM, LLC appears as the correspondent for the assignments to and from FITLINXX, INC. (reels 038590/0815, 041038/0102, and 046755/0733). This indicates consistent legal representation for specific parties involved in the chain.
4. Cascading transfers — not present. The transfers, particularly those involving Fitlinxx and Lumiradx, are not rapid consecutive assignments within a short timeframe between related LLCs. The security interest grants are distinct from transfers of ownership.
5. Pre-litigation transfer — unclear. Without information on the first infringement suit filing date for this specific patent, it is not possible to determine if any assignment occurred within 6 months prior.
6. Bankruptcy fire-sale — not present. There is no indication in the assignment records or publicly available information that Welch Allyn Inc. or any subsequent operating company assignor filed for bankruptcy and sold off its patent assets.
7. Privateering — not present. There is no evidence from the assignment records to suggest an operating company transferred the patent to an NPE to assert on its behalf.
8. Defensive aggregator (anti-NPE) — not present. The chain does not terminate at any known defensive aggregators like RPX, AST, LOT Network, Unified Patents, or Open Invention Network.

Verdict

Insufficient data. While there are repeat correspondents for different segments of the assignment chain (McDermott Will & Emery for the JPMorgan security interests, and Wetzel Law Firm for the Fitlinxx/Lumiradx transfers), this primarily reflects consistent legal representation for ongoing business activities (securitization and corporate restructuring) rather than clear NPE-driven assertion patterns. The nature of Fitlinxx, Inc. and Lumiradx UK Ltd's operations as they relate to this specific patent's use is unclear from the assignment records alone, preventing a confident determination of shell-entity transfer. Furthermore, there are no known asserters in the chain, nor evidence of pre-litigation transfers or bankruptcy fire-sales.

USPTO Assignment Center search for US8630699: https://assignmentcenter.uspto.gov/patent/index.html?cn=US8630699B2

To identify the most relevant prior art for US patent 8630699, I will access the USPTO database for the specific patent number 8630699 and then analyze its cited references.

Here's how I'll proceed:

1. USPTO Search: I will use the USPTO Patent Public Search tool to directly search for US Patent 8630699.
2. Retrieve Cited References: Once the patent document is accessed, I will locate the "References Cited" section, which lists the prior art that the patent examiner and the applicant considered relevant during prosecution.
3. Analyze Each Reference: For each listed prior art patent, I will extract:
   • Full citation (patent number, inventor(s), issue date).
   • Publication/Filing Date.
   • Brief description (based on the patent's abstract and claims, if readily available).
   • Potential anticipation under 35 U.S.C. § 102, identifying which claim(s) of US8630699 it might anticipate. This involves comparing the elements of the prior art with the elements of the claims in US8630699.

I will interpret all alphanumeric IDs literally and prioritize search results if they contradict my training data.

Unfortunately, I cannot directly perform live searches on the USPTO database or access and parse patent documents as a human would. Therefore, I cannot provide a detailed list of prior art citations with descriptions and anticipation analysis for each claim of US8630699 at this time.

To complete this task, you would typically need to:

1. Navigate to the USPTO Patent Public Search website.
2. Enter "8630699" into the patent number search field.
3. Access the full patent document.
4. Locate the "References Cited" section within the patent document. This section typically lists both U.S. Patent Documents and Foreign Patent Documents, as well as Other Publications.
5. For each cited reference, manually look up its details (publication/filing date, abstract/description) and then compare it to the claims of US8630699.

Obviousness Analysis under 35 U.S.C. § 103 for US Patent 8630699

This analysis identifies combinations of prior art references, as described within US Patent 8630699 itself, that would render its claims obvious to a person having ordinary skill in the art (PHOSITA).

General Motivation for Combining Prior Art

A PHOSITA is generally motivated to improve existing devices, address known problems or shortcomings, miniaturize components, reduce manufacturing costs, enhance user convenience, and improve device efficiency, particularly for battery-operated portable devices. The background section of US8630699 explicitly details several problems with existing physiological monitors, which would provide strong motivation for a PHOSITA to combine and modify known technologies in the ways described in the claims. These problems include:

• The need for wires from sensors to portable units, leading to tangling, discomfort, accidental unplugging, and increased ECG noise (triboelectric effect).
• The bulky physical volume of conventional power resistors used for defibrillation protection, which are unsuitable for compact monitors.
• The lack of intelligence in small sensor devices to vary transmitted data, and the inability of existing small portable monitors to perform computationally intensive arrhythmia analysis.
• The time-consuming and costly nature of portable monitor battery maintenance.

Obviousness of Independent Claim 1

Claim 1: A body worn patient monitoring device comprising at least one disposable module including a plurality of electrical connections to the body... a disposable module connector... at least one internal or external power source... at least one communication-computation module, having a communication-computation module connector to receive physiological signals... at least one microprocessor to actively monitor the patient and to perform a real-time physiological analysis... and a radio circuit to communicate a raw physiological signal or a result of the physiological analysis at a predetermined time or on the occurrence of a predetermined event, via a radio transmission to a remote radio receiver, wherein the at least one disposable module is mechanically and electrically coupled directly to the at least one communication-computation module, and wherein the body worn patient monitoring device... is directly non-permanently affixed to the skin surface of the patient.

Prior Art Combination:

1. "Micropaq wireless patient monitor" (Welch Allyn, Inc.): This device is described as a "small, rugged, lightweight, patient-wearable device" that "permits multi-parameter monitoring and patient alarm capabilities" and "transmits the sensed heart beat... by wireless techniques, the sensor transmits the sensed heart beat to a nearby microcomputer based monitor and display." This reference teaches a body-wearable device with wireless communication and a microcomputer.
2. General "Portable patient monitors" and "Heart rate monitor typically used by individuals engaged in an athletic activity": These references teach that "sensors, such as ECG electrodes, are affixed to the patient's body, such as with tape, and connected to the battery operated monitor by wires." They also confirm the use of battery power for portability.
3. Explicit Problem Statement in US8630699 Background: The patent highlights the "recurrent problem with the portable monitors typically used in healthcare applications is the need for wires from sensors situated on the patient's body to the portable unit."
4. Common medical practice: The use of disposable electrodes is well-established in the medical field for hygiene and convenience.
5. U.S. patent application Ser. No. 11/031,736: This is incorporated by reference for "details of such monitoring networks" and describes an "integrated wireless monitoring network."

Motivation for Combination:
A PHOSITA would be strongly motivated to eliminate the "recurrent problem" of wires in portable patient monitors, as articulated in the patent's background. Given that the "Micropaq wireless patient monitor" already demonstrated a "patient-wearable" device with "wireless techniques" and a "microcomputer", the next logical step to eliminate wires would be to integrate the sensors directly into the device rather than connecting them via external leads. The common practice of disposable electrodes would motivate placing them in a disposable module. Attaching this disposable module directly to the computation/communication module, and then affixing the entire integrated unit directly to the patient's skin, directly addresses the wire problem, improves patient comfort, and reduces noise. The motivation to incorporate "real-time physiological analysis" and intelligent wireless communication "at a predetermined time or on the occurrence of a predetermined event" is clearly stated in the patent as a solution to the shortcomings of existing small devices that "lack the intelligence to vary the amount and type of data transmitted" or cannot perform "arrhythmia analysis." The "U.S. patent application Ser. No. 11/031,736" further reinforces the motivation for integrated wireless monitoring networks.

Obviousness of Independent Claim 12

Claim 12: A method of providing high voltage circuit protection for a body worn monitor comprising the steps of: providing a substrate that supports one or more electrical connections to a patient's body; determining a print pattern and thickness of a first material having a first resistivity to be printed on the substrate; determining a print pattern and thickness of a second material having a second resistivity to be printed on the substrate; printing the first material onto the substrate; and printing the second material onto the substrate wherein at least part of the second material overlays the first material.

Prior Art Combination:

1. Conventional defibrillation protection: The patent states that the requirement for medical-grade monitors to "survive multiple defibrillation cycles of at least 360 joules" has "Conventionally... been met by one or more power resistors situated in series with the wire leads of a fixed or portable physiological monitor."
2. Problem statement in US8630699 Background: "The problem is that the physical volume of conventional power resistors is too large for use in a compact monitor application."
3. Known manufacturing techniques: Screen printing, the use of various inks (e.g., carbon, silver) with different resistivities, and the concept of layering materials on a substrate were well-known in the art of printed electronics and circuit board manufacturing. The patent itself describes using "silk screen printing method" to deposit "carbon paste conductor" and "silver ink" on a "Mylar substrate." The patent also discusses overlaying materials (e.g., "a carbon annulus pattern can be deposited before the conductive surface 404 is deposited. Conductive surface 404 can then be deposited as an overlay over the earlier formed carbon annulus shape").

Motivation for Combination:
A PHOSITA, faced with the explicit problem of the "physical volume of conventional power resistors" being "too large for use in a compact monitor application", would be motivated to find a miniaturized solution for defibrillation protection. Given the widespread knowledge of printing techniques for creating conductive and resistive traces on flexible substrates, it would be obvious to replace bulky discrete resistors with printed resistive elements directly on the electrode substrate. The use of different materials with varying resistivities (e.g., carbon for high resistance, silver for conductivity) and the technique of overlaying these materials to form integrated traces are standard practices in printed circuit design to achieve specific electrical properties and robust connections. The patent's own detailed description of solving "arcing at the interface between the carbon and conductive traces" by overlaying or using fillet shapes suggests that a PHOSITA would be aware of these challenges and corresponding solutions in combining such materials. Thus, applying these known printing and layering methods to create compact, defibrillation-resistant traces for a body-worn monitor would be an obvious design choice to solve the stated problem of size.

Obviousness of Independent Claim 17

Claim 17: A body worn patient monitoring device comprising: means for performing real-time physiological analysis of signals from a patient; a radio for communicating results of the real-time physiological analysis at a predetermined time or on the occurrence of a predetermined event; and a power management circuit configured to reduce power consumption by causing the device to enter a sleep mode during periods when useful physiological data is not being acquired and to exit the sleep mode to actively monitor the patient and perform the real-time physiological analysis.

Prior Art Combination:

1. "Micropaq wireless patient monitor": This device is a "patient-wearable device" with "multi-parameter monitoring and patient alarm capabilities" and a "microcomputer" that transmits sensed heartbeats wirelessly. This provides the body-worn aspect, a processing unit, and wireless communication.
2. Problem statements in US8630699 Background: The patent identifies that "portable monitor battery maintenance (e.g. battery recharging or replacement) can be time consuming and costly" and that existing small devices "lack the intelligence to vary the amount and type of data transmitted."
3. General knowledge of power management in battery-operated electronics: It was well-known in the art of portable, battery-powered electronic devices (e.g., cell phones, athletic monitors, other medical devices) to implement power-saving features such as "sleep modes" or "power-down modes" for microprocessors and circuits during periods of inactivity to extend battery life.
4. Patent's own description of power saving: "When viewed over time, most of the ECG waveform does not contain useful information since there is significant 'dead time' between heart beats. For this reason, circuits can be powered down (in a device 'sleep mode') to save on the order of 60% of the energy stored in the power source that would have otherwise been used during this dead time." The patent also describes putting the "microcontroller and/or other circuits...into a sleep mode during an ADC conversion cycle" and "buffering" data to batch-process it.

Motivation for Combination:
A PHOSITA concerned with the "time consuming and costly" battery maintenance for portable patient monitors would be highly motivated to implement power-saving strategies. Given that the "Micropaq wireless patient monitor" already included a "microcomputer" and wireless communication in a "patient-wearable device", integrating "real-time physiological analysis" into such a device would address the identified "shortcoming" of small devices lacking intelligence. It would be an obvious step for a PHOSITA to apply known power management techniques, such as sleep modes, to these computationally capable, battery-powered, body-worn devices. The patent explicitly states that "most of the ECG waveform does not contain useful information since there is significant 'dead time' between heart beats," thereby providing a clear justification for entering a sleep mode during such periods. The intelligent communication of results "at a predetermined time or on the occurrence of a predetermined event" further supports the efficiency of the power management, as the radio would not need to be constantly active.

Obviousness of Independent Claim 18

Claim 18: A body worn patient monitoring device comprising: a first portion being disposable, the first portion including at least one electrode for attachment to a patient's body and a power source; a second portion being reusable and detachably coupled to the first portion, the second portion including a microprocessor for actively monitoring the patient and a radio circuit for wireless communication of physiological signals or results of physiological analysis; and wherein the body worn patient monitoring device is configured to be directly, non-permanently affixed to the patient's body.

Prior Art Combination:

1. General "Portable patient monitors": These monitors use "sensors, such as ECG electrodes, are affixed to the patient's body, such as with tape" and are "battery operated."
2. "Micropaq wireless patient monitor": A "patient-wearable device" with "multi-parameter monitoring and patient alarm capabilities" and a "microcomputer" that transmits heartbeats "by wireless techniques."
3. Problem statement in US8630699 Background: The patent identifies a need for "a body worn combined physiological sensor and monitor having a disposable sensor, but used and worn by a patient as a single unit directly and non-permanently affixed to a patient's body."
4. Common medical device design principles: It is well-known to separate medical devices into disposable (consumable, single-use, or short-term use) and reusable (expensive electronics, long-term use) components for hygiene, cost-effectiveness, and ease of replacement.
5. Patent's own disclosure of components: The patent clearly describes "a removable and reusable communications and computation module 102 and a disposable electrode module 110," where the disposable module includes "electrode gels 103... and batteries 204 to power communications and computation module 102." It also details a "retention clip 104, to mechanically attach communications and computation module 102 to the top surface of the disposable electrode module 110."

Motivation for Combination:
A PHOSITA, seeking to fulfill the stated need for a "body worn combined physiological sensor and monitor having a disposable sensor" and addressing the high cost and maintenance of traditional medical monitors, would be motivated to design a modular system. The widely adopted practice of using disposable electrodes for medical monitoring, combined with the desirability of a reusable electronics core (like the "microcomputer" and wireless capabilities of the Micropaq), would naturally lead to a two-part design. Placing the power source (batteries) in the disposable portion alongside the electrodes is an obvious design choice to simplify maintenance for the user – replacing the entire disposable module, which includes components that degrade with use (electrodes) and components that deplete (batteries), in one step. The mechanical and electrical "detachable coupling" would be implemented using standard connectors and clips, as taught by the patent's own figures and description (e.g., retention clip 104). The configuration of the entire device to be "directly, non-permanently affixed to the patient's body" is driven by the patent's explicit goal of eliminating external wires and their associated problems.

To provide a comprehensive analysis of US Patent 8630699, I will detail any patent term adjustments (PTA), patent term extensions (PTE), continuation applications, divisional applications, related family members, and the projected expiration date, drawing upon information from the USPTO database.

Patent Term Adjustments (PTA)

Patent Term Adjustment (PTA) can be granted to a patent to compensate for administrative delays by the USPTO during prosecution. These delays fall into categories such as: "A delay" (e.g., USPTO failing to issue an office action within 14 months of filing, or responding to an applicant's reply within four months), "B delay" (the application pending for more than three years), and "C delay" (delays due to interference, secrecy orders, or appellate review). The total PTA is the sum of these delays, minus any overlapping periods and applicant-caused delays.

To determine the exact PTA for US Patent 8630699, direct access to the USPTO's Patent Center or the Patent Term Adjustment API with the application number (US13/488,520) would be necessary. The provided patent information indicates that applications filed after May 28, 2000, are subject to PTA rules. Since US8630699 was filed on June 5, 2012, it is eligible for PTA. Without specific PTA data from the USPTO for this patent, the exact adjustment amount cannot be stated here.

Patent Term Extensions (PTE)

Patent Term Extension (PTE) is granted under 35 U.S.C. § 156 to restore patent term lost due to premarket regulatory review for certain products, such as human drugs, medical devices, animal drugs, and food or color additives. Only one patent can be extended for a regulatory review period for any given product. PTE is distinct from PTA and is not affected by terminal disclaimers.

Given that US Patent 8630699 relates to a "body worn physiological sensor device having a disposable electrode module," it could potentially be eligible for PTE if a product covered by its claims underwent regulatory review by an agency like the FDA. Specifically, medical devices subject to review under section 515 of the Federal Food, Drug, and Cosmetic Act (FFDCA), which are Class III high-risk devices, are eligible for PTE. Without information on specific regulatory approval for a product covered by this patent, it's not possible to definitively state whether PTE has been applied or granted to US8630699. To determine this, one would typically need to consult the USPTO's lists of applications for patent term extension or certificates of extension, often found in Patent Center.

Continuation and Divisional Applications

The patent text explicitly states that US8630699 is a continuation application of, and claims priority and benefit to, U.S. Pat. No. 8,214,007 B2, entitled "Body Worn Device Having a Disposable Electrode Module," filed November 1, 2006.

The patent also lists several other patents and applications with priority dates related to US8630699. These likely represent continuation or divisional applications:

• Priority to US14/103,219 (publication of US8750974B2/en) on 2013-12-11.
• Priority to US14/268,666 (publication of US8965492B2/en) on 2014-05-02.
• Priority to US14/595,815 (publication of US9155484B2/en) on 2015-01-13.
• Priority to US14/880,413 (publication of US9433366B2/en) on 2015-10-12.
• Priority to US14/880,366 (publication of US20160029917A1/en) on 2015-10-12.
• Priority to US15/237,719 (publication of US9877663B2/en) on 2016-08-16.
• Priority to US15/880,712 (publication of US10159422B2/en) on 2018-01-26.
• Priority to US16/215,698 (publication of US10939839B2/en) on 2018-12-11.

These indicate a family of related patents and applications that build upon the original disclosure. A patent granted on a continuation or divisional application filed after June 8, 1995, will have a term ending twenty years from the filing date of the earliest application for which a benefit is claimed.

Related Family Members

As indicated above, US8630699 is a continuation of US8214007B2. The multiple priority claims listed above (US14/103,219, US14/268,666, US14/595,815, US14/880,413, US14/880,366, US15/237,719, US15/880,712, US16/215,698) are all related family members, likely representing additional continuation or divisional applications that stem from the same original subject matter or an earlier application in the priority chain.

Projected Expiration Date

The "Anticipated expiration" date listed in the patent details is November 1, 2026. This date is derived from the priority date of November 1, 2006, and the general rule that utility patents have a term of 20 years from the earliest filing date from which priority is claimed (in this case, the parent application US Pat. No. 8,214,007 B2).

This projected expiration date does not appear to include any potential Patent Term Adjustment (PTA) or Patent Term Extension (PTE). The USPTO does not calculate expiration dates for patents, but provides resources and calculators for estimation, considering factors like PTA, PTE, and terminal disclaimers. If PTA or PTE were granted, the actual expiration date could be later than November 1, 2026.

As a Senior Patent Strategist and Research Engineer specializing in Defensive Publishing, my objective is to generate comprehensive "Defensive Disclosure" material for US Patent 8630699. This disclosure aims to create "Prior Art" that could render future incremental improvements by competitors "obvious" or "non-novel" by exploring derivative variations across several axes for each core independent claim.

The analysis is based on Independent Claims 1, 12, 17, and 18 as outlined in the previously generated sections.

---

Derivatives of Independent Claim 1: Body worn patient monitoring device (disposable module + communication-computation module, direct coupling, non-permanently affixed)

Derivative 1.1: Material & Component Substitution (Dry Electrodes & Flexible Hybrid Electronics)

• Enabling Description: A body-worn patient monitoring device is disclosed wherein the disposable module incorporates solid-state, non-gelled "dry electrodes" composed of an array of micro-needles or conductive polymer composites (e.g., polypyrrole, PEDOT:PSS) directly integrated into a flexible hybrid electronic (FHE) substrate fabricated from polyimide film. The disposable module connector is implemented as a zero-insertion-force (ZIF) elastomer connector, employing an anisotropic conductive film (ACF) interface to ensure robust and repeatable electrical coupling with the reusable communication-computation module. The power source within the disposable module is a flexible thin-film lithium-ion battery, precisely silk-screen printed onto the polyimide substrate itself. The radio circuit for wireless data transmission employs an ultra-low-power Bluetooth Low Energy (BLE) System-on-Chip (SoC) for energy-efficient communication of physiological data.

  graph TD
      A[Patient Skin] -- Dry Electrodes (Micro-needle array, Conductive polymer) --> B{Disposable Module (Polyimide FHE)}
      B -- ZIF Elastomer Connector (ACF) --> C{Communication-Computation Module}
      B -- Flexible Thin-Film Li-Ion Battery --> C
      C -- Microprocessor & Real-time Analysis --> D[Radio Circuit (BLE SoC)]
      D -- Wireless Transmission --> E[Remote Receiver]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style C fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style D fill:#cff,stroke:#333,stroke-width:2px,color:#000
      style E fill:#fcc,stroke:#333,stroke-width:2px,color:#000
  

Derivative 1.2: Material & Component Substitution (Capacitive Textile Electrodes & Inductive Coupling)

• Enabling Description: This derivative features a body-worn physiological monitor utilizing a disposable textile-based module wherein capacitive "dry" textile electrodes, fabricated by weaving silver-coated conductive fibers (e.g., Ag/PA6.6 yarn) into a stretchable fabric substrate, achieve physiological signal acquisition without direct galvanic contact. The disposable module incorporates an integrated power source consisting of flexible supercapacitors woven into the textile. The mechanical and electrical coupling between this disposable textile module and the communication-computation module is realized through inductive coil coupling, facilitating simultaneous wireless power transfer and bidirectional data exchange. This inductive interface enables hermetically sealed modules and simplifies detachment/reattachment. The communication-computation module contains a custom Application-Specific Integrated Circuit (ASIC) for real-time physiological signal conditioning and a UWB (Ultra-Wideband) radio for high-bandwidth, short-range data bursts.

  graph TD
      A[Patient Skin] -- Capacitive Textile Electrodes (Ag-coated fibers) --> B{Disposable Textile Module (Stretchable Fabric)}
      B -- Inductive Coupling (Power & Data) --> C{Communication-Computation Module}
      B -- Flexible Supercapacitors --> C
      C -- Custom ASIC & Real-time Analysis --> D[Radio Circuit (UWB)]
      D -- Wireless Transmission --> E[Remote Receiver]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style C fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style D fill:#cff,stroke:#333,stroke-width:2px,color:#000
      style E fill:#fcc,stroke:#333,stroke-width:2px,color:#000
  

Derivative 1.3: Operational Parameter Expansion (Nanoscale Integrated Biosensors for Multi-omics)

• Enabling Description: A body-worn patient monitoring device is described that integrates advanced nanoscale biosensors within its disposable module. This includes an array of plasmonic gold nanoparticles functionalized with specific aptamers for detecting protein biomarkers (e.g., troponin I for cardiac events) and microfluidic channels designed for continuous interstitial fluid sampling, enabling real-time glucose and lactate monitoring. The electrical connections from these biosensors are established via direct solid-state interfaces to the communication-computation module. The communication-computation module, operating at ultra-high sampling rates (e.g., >10 kHz per channel) and utilizing dedicated Digital Signal Processors (DSPs), performs real-time multi-omics data analysis. Critical alerts and processed data are communicated via a LoRaWAN radio circuit to a remote cloud platform. The device is non-permanently affixed using a biocompatible adhesive hydrogel layer formulated for prolonged patient wear.

  graph TD
      A[Patient Skin/Interstitial Fluid] -- Nanoscale Biosensors (Plasmonic NPs, Microfluidics) --> B{Disposable Module (Micro-fabricated wafer)}
      B -- Direct Electrical Interface --> C{Communication-Computation Module (DSPs)}
      B -- Integrated Micro-battery --> C
      C -- Real-time Multi-omics Analysis --> D[Radio Circuit (LoRaWAN)]
      D -- Wireless Transmission (Cloud) --> E[Remote Platform]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style C fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style D fill:#cff,stroke:#333,stroke-width:2px,color:#000
      style E fill:#fcc,stroke:#333,stroke-width:2px,color:#000
  

Derivative 1.4: Cross-Domain Application (Aerospace Astronaut Vital Signs Monitoring)

• Enabling Description: A body-worn physiological monitoring device specifically engineered for astronaut vital sign monitoring within microgravity environments. The disposable module integrates multi-lead ECG electrodes, non-invasive blood pressure (NIBP) sensors based on photoplethysmography, and galvanic skin response (GSR) sensors. These are all embedded into a flexible, conformable garment-like patch constructed from space-rated, fire-retardant silicone composite materials. The electrical connections are direct dermal contacts. The disposable module mechanically and electrically couples to a hardened, radiation-shielded communication-computation module via a robust multi-pin connector. The module's microprocessor executes real-time arrhythmia detection, stress level analysis derived from GSR, and NIBP trend monitoring, transmitting the processed data via a proprietary, low-latency, frequency-hopping spread spectrum (FHSS) radio link to the International Space Station (ISS) central telemetry system. The entire assembly is non-permanently affixed to the astronaut's torso utilizing a medical-grade, micro-adhesive film designed for reliable skin adhesion across various atmospheric pressures.

  graph TD
      A[Astronaut Torso (Microgravity)] -- Multi-lead ECG, NIBP, GSR (flexible garment) --> B{Disposable Module (Silicone Composite)}
      B -- Radiation-shielded Connector --> C{Hardened Comms-Comp Module}
      B -- Integrated Power Cell --> C
      C -- Real-time Arrhythmia, Stress, NIBP Analysis --> D[Radio Circuit (FHSS)]
      D -- Low-latency Transmission --> E[ISS Telemetry System]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style C fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style D fill:#cff,stroke:#333,stroke-width:2px,color:#000
      style E fill:#fcc,stroke:#333,stroke-width:2px,color:#000
  

Derivative 1.5: Integration with Emerging Tech (AI-Driven Predictive Diagnostics & IoT Mesh)

• Enabling Description: This body-worn patient monitoring device incorporates an embedded AI inference engine (e.g., a lightweight Convolutional Neural Network or LSTM network) running on the communication-computation module's microprocessor. This AI performs predictive diagnostics for cardiac events (e.g., pre-symptomatic detection of atrial fibrillation) by analyzing subtle, multi-variate patterns within ECG waveforms, alongside data from integrated IoT sensors (e.g., skin temperature via thermistor, motion activity via 3-axis accelerometer, ambient environmental data via a MEMS-based multi-sensor array). The radio circuit communicates encrypted physiological data, AI-generated risk scores, and environmental context via a secure, self-healing IoT mesh network (e.g., implementing Thread or Zigbee IP protocols) to a local gateway. This gateway then securely relays data to a cloud-based medical AI platform for secondary validation and clinical decision support. The "predetermined event" triggering high-bandwidth or priority transmission is dynamically determined by the AI when a confidence score for a critical event exceeds a dynamically adjusted threshold.

  graph TD
      A[Patient Skin] -- Electrodes & IoT Sensors (Temp, Humidity, Accel) --> B{Disposable Module}
      B -- Connector --> C{Communication-Computation Module}
      B -- Power Source --> C
      C -- Microprocessor (Embedded AI Inference Engine) --> D[Radio Circuit (IoT Mesh: Thread/Zigbee IP)]
      D -- Encrypted Data & AI Risk Scores --> E[Local IoT Gateway]
      E -- Cloud-based Medical AI Platform --> F[Clinician Decision Support]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style C fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style D fill:#cff,stroke:#333,stroke-width:2px,color:#000
      style E fill:#fcc,stroke:#333,stroke:#333,stroke-width:2px,color:#000
      style F fill:#cfc,stroke:#333,stroke-width:2px,color:#000
  

Derivative 1.6: The "Inverse" or Failure Mode (Adaptive Low-Power Emergency Mode)

• Enabling Description: A body-worn patient monitoring device is disclosed with an adaptive low-power emergency mode. Upon detection of a critical power threshold (e.g., rechargeable battery charge below 10% State of Charge (SoC)) or a "lead-off" event for a primary physiological electrode (identified via impedance monitoring), the microprocessor actively transitions to a sleep-optimized state. In this mode, non-essential physiological monitoring algorithms (e.g., detailed ST-segment analysis, high-resolution arrhythmia detection) are suspended. The device reduces its sampling rate for essential parameters (e.g., switches to basic heart rate detection from a single remaining viable electrode, or switches to intermittent pulse oximetry). Concurrently, the radio circuit transitions to a periodic, low-duty-cycle beacon mode, transmitting only critical "SOS" alerts, a timestamp, and last known vital signs via a long-range, low-power wide-area network (LPWAN) protocol like NB-IoT. This strategy ensures prolonged operational capability for emergency signaling and coarse location tracking, even under severely degraded power or sensor connectivity conditions, prioritizing patient safety over comprehensive data acquisition.

  stateDiagram-v2
      [*] --> ActiveMonitoring: Power On
      ActiveMonitoring --> LowPowerEmergency: Battery < 10% or Lead-Off
      LowPowerEmergency --> ActiveMonitoring: Battery Recharged or Lead-On
      ActiveMonitoring --> DeepSleep: No activity / Manual Disable
      LowPowerEmergency --> DeepSleep: Critical Failure / Manual Disable
      DeepSleep --> ActiveMonitoring: External Wakeup / Timer
      
      state ActiveMonitoring {
          HighSamplingRate
          FullPhysiologicalAnalysis
          ContinuousRadioTx
      }
      
      state LowPowerEmergency {
          ReducedSamplingRate
          BasicHRDetection
          PeriodicLPWANBeacon: SOS alerts, Last Vitals
      }
      
      state DeepSleep {
          MinimalPowerConsumption
          NoMonitoring
      }
      style ActiveMonitoring fill:#cfc,stroke:#333,stroke-width:2px,color:#000
      style LowPowerEmergency fill:#fcc,stroke:#333,stroke-width:2px,color:#000
      style DeepSleep fill:#ccc,stroke:#333,stroke-width:2px,color:#000
  

---

Derivatives of Independent Claim 12: Method for providing high voltage circuit protection for a body worn monitor

Derivative 12.1: Material & Component Substitution (Graphene/CNT Inks & ALD Dielectric)

• Enabling Description: A method for high-voltage circuit protection is described, wherein the flexible substrate consists of a transparent PEN (polyethylene naphthalate) film. The first material, providing high resistivity, is a graphene/carbon nanotube (CNT) composite ink, screen-printed in a precise serpentine pattern. The resistivity of this ink is finely tunable by adjusting the precise ratio of graphene to CNTs during formulation. The second material, functioning as the primary conductor with lower resistivity, is a silver nanowire (AgNW) ink, selectively inkjet-printed to overlay specific sections of the graphene/CNT trace. Following the printing steps, a subsequent protective dielectric layer is applied via Atomic Layer Deposition (ALD) of Aluminum Oxide (Al2O3). This ALD process offers superior conformality and dielectric breakdown strength compared to conventional screen-printed dielectrics, precisely encapsulating and isolating the resistive traces to effectively prevent arcing under high voltage transients.

  graph TD
      A[PEN Substrate] --> B{Determine Print Pattern & Thickness (Graphene/CNT, AgNW)}
      B --> C[Screen Print Graphene/CNT Ink (High Resistivity)]
      C --> D[Inkjet Print AgNW Ink (Low Resistivity) - Overlays]
      D --> E[ALD Al2O3 Dielectric Layer]
      E --> F[Protected Electrical Connection]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#cfc,stroke:#333,stroke-width:2px,color:#000
      style C fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style D fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style E fill:#cff,stroke:#333,stroke-width:2px,color:#000
      style F fill:#fcc,stroke:#333,stroke-width:2px,color:#000
  

Derivative 12.2: Operational Parameter Expansion (Industrial High-Power Protection for Smart Grid)

• Enabling Description: A method for providing high-voltage circuit protection is applied to industrial smart grid components, such as integrated circuit breakers or overcurrent protection modules for grid sensor nodes operating at several kilovolts. The substrate for these components is a ceramic-filled polymer composite, specifically chosen for its robust thermal stability and high dielectric strength. The first resistive material is a thick-film cermet paste (e.g., ruthenium dioxide-based), precisely deposited by stencil printing to form robust resistive tracks with resistance values extending into the megohm range. The second material is a high-current copper paste, screen-printed over the cermet layer to define controlled breakdown points or current limiting sections. This overlay design ensures optimal thermal coupling and uniform current distribution during high-energy surge events. The manufacturing process includes a high-temperature sintering step to achieve robust, long-lasting protective elements capable of dissipating substantial transient energies derived from phenomena such as lightning strikes or grid faults.

  graph TD
      A[Ceramic-Filled Polymer Substrate] --> B{Determine Cermet & Copper Patterns (Megohm range)}
      B --> C[Stencil Print Cermet Paste (High Resistivity)]
      C --> D[Screen Print Copper Paste (Low Resistivity) - Overlays]
      D --> E[High-Temperature Sintering]
      E --> F[Industrial High-Voltage Protection (Smart Grid)]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#cfc,stroke:#333,stroke-width:2px,color:#000
      style C fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style D fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style E fill:#cff,stroke:#333,stroke-width:2px,color:#000
      style F fill:#fcc,stroke:#333,stroke-width:2px,color:#000
  

Derivative 12.3: Cross-Domain Application (Flexible Automotive Heater Elements with Protection)

• Enabling Description: A method for manufacturing flexible automotive heater elements with integrated overcurrent protection for applications like window defrosting or seat heating. The substrate is a robust, automotive-grade flexible polyimide film, chosen for its durability and temperature resistance. The first material, a Positive Temperature Coefficient (PTC) ink based on carbon black dispersed in a specific polymer matrix, is gravure-printed to form a resistive heating grid. This PTC characteristic intrinsically limits current at elevated temperatures, providing inherent thermal protection. The second material, a highly conductive silver paste, is flexographically printed to create low-resistance busbars and localized current-limiting structures that precisely overlay critical junctions of the PTC grid. This design ensures uniform heat distribution while the PTC material provides self-regulating thermal protection, and the silver overlay defines zones for specific current handling and distribution, safeguarding against localized hotspots and overcurrent conditions.

  graph TD
      A[Automotive-Grade Polyimide Substrate] --> B{Determine PTC Ink & Silver Paste Patterns}
      B --> C[Gravure Print PTC Ink (Resistive Heating Grid, High Resistivity/Temp)]
      C --> D[Flexo Print Silver Paste (Busbars, Low Resistivity) - Overlays]
      D --> E[Curing/Lamination]
      E --> F[Flexible Automotive Heater with Overcurrent Protection]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#cfc,stroke:#333,stroke-width:2px,color:#000
      style C fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style D fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style E fill:#cff,stroke:#333,stroke-width:2px,color:#000
      style F fill:#fcc,stroke:#333,stroke:#333,stroke-width:2px,color:#000
  

Derivative 12.4: Integration with Emerging Tech (AI-Optimized Self-Healing Traces)

• Enabling Description: A method for high-voltage circuit protection where an AI-driven optimization algorithm, utilizing finite element analysis (FEA) and machine learning (ML), autonomously determines the optimal print patterns and thicknesses for both resistive and conductive materials. The substrate is a self-healing polymer composite, capable of autonomously repairing minor mechanical damage (e.g., micro-cracks). The first material is a composite resistive ink embedded with microcapsules containing a conductive healing agent (e.g., liquid metal alloy or carbon nanoparticle dispersion). The second material is a standard silver ink. The AI algorithm simulates various defibrillation pulse profiles and environmental stresses to optimize trace geometries (e.g., fillets, variable widths, fractal patterns) and material overlay regions. This optimization aims to maximize energy dissipation and minimize degradation, while concurrently facilitating the self-healing mechanism. Upon detection of micro-damage (e.g., via integrated strain sensors), the healing agent is released, restoring the original conductivity and resistance profiles of the trace.

  graph TD
      A[Self-Healing Polymer Substrate] --> B{AI Optimization Algorithm: FEA, ML}
      B -- Output: Print Patterns & Thicknesses --> C[Print Resistive Ink with Microcapsules (Self-Healing)]
      C --> D[Print Silver Ink (Conductive) - AI-Optimized Overlays]
      D --> E[Curing/Activation]
      E --> F[Self-Healing High-Voltage Protection]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#cfc,stroke:#333,stroke-width:2px,color:#000
      style C fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style D fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style E fill:#cff,stroke:#333,stroke-width:2px,color:#000
      style F fill:#fcc,stroke:#333,stroke:#333,stroke-width:2px,color:#000
  

Derivative 12.5: The "Inverse" or Failure Mode (Sacrificial, Disintegrating Trace)

• Enabling Description: This method provides high-voltage circuit protection by designing the resistive traces to function as sacrificial, single-event fuses that safely disintegrate upon exposure to a predetermined overvoltage event exceeding typical defibrillation levels. This disintegration physically isolates the sensitive electronics from further damage. The substrate for this design is a photoresist-patterned thin-film ceramic. The first material is a highly brittle, high-resistance nickel-chromium (NiCr) alloy sputtered onto the ceramic in a precisely narrow trace. The second material, a low-melting-point bismuth-tin (BiSn) alloy, is selectively deposited via electroplating to partially overlay and reinforce specific segments of the NiCr trace. Upon an extreme overvoltage transient, the NiCr trace rapidly heats due to resistive dissipation and then fractures, while the BiSn alloy melts and disperses, resulting in the creation of a permanent open circuit. This mechanism prevents cascading failures and renders the disposable module clearly and irreversibly inoperable post-event.

  graph TD
      A[Photoresist-Patterned Thin-Film Ceramic Substrate] --> B{Determine NiCr & BiSn Patterns}
      B --> C[Sputter NiCr Alloy (Brittle, High Resistivity)]
      C --> D[Electroplate BiSn Alloy (Low-Melting Point) - Partial Overlays]
      D --> E[Post-processing/Annealing]
      E --> F[Sacrificial Disintegrating Trace Protection]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#cfc,stroke:#333,stroke-width:2px,color:#000
      style C fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style D fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style E fill:#cff,stroke:#333,stroke-width:2px,color:#000
      style F fill:#fcc,stroke:#333,stroke:#333,stroke-width:2px,color:#000
  

---

Derivatives of Independent Claim 17: Body worn patient monitoring device (real-time analysis, radio, power management sleep mode)

Derivative 17.1: Material & Component Substitution (Neuromorphic Processor & Backscatter Radio)

• Enabling Description: A body-worn patient monitoring device where the "means for performing real-time physiological analysis" is implemented using a low-power neuromorphic processor (e.g., based on spiking neural network architectures like IBM TrueNorth). This processor operates on event-driven principles, significantly reducing power consumption by only activating neuronal cores and processing units in response to detected physiological signal transients (e.g., QRS complex detection, seizure onset activity). The "radio for communicating results" is a passive backscatter radio. This radio passively modulates and reflects ambient RF energy transmitted from a dedicated external interrogator, thereby eliminating the need for an active onboard RF transmitter and dramatically extending the operational lifespan by conserving battery power. The power management circuit intelligently orchestrates the neuromorphic processor's sleep cycles with the intermittent availability of ambient RF energy for efficient data offloading.

  graph TD
      A[Physiological Signals] --> B{Neuromorphic Processor (Event-Driven Analysis)}
      B -- Analysis Results --> C[Power Management Circuit]
      C -- Control (Sleep/Active) --> B
      C --> D{Backscatter Radio (Passive)}
      D -- Reflect Ambient RF --> E[External RF Interrogator/Receiver]
      E -- Decoded Data --> F[Remote System]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#cfc,stroke:#333,stroke-width:2px,color:#000
      style C fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style D fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style E fill:#cff,stroke:#333,stroke-width:2px,color:#000
      style F fill:#fcc,stroke:#333,stroke-width:2px,color:#000
  

Derivative 17.2: Operational Parameter Expansion (Ultra-Long-Term Brain-Computer Interface (BCI) Monitor)

• Enabling Description: A body-worn patient monitoring device configured as an ultra-long-term, non-invasive Brain-Computer Interface (BCI) monitor for continuous neurological assessment (e.g., epilepsy management, sleep disorder diagnosis, cognitive load monitoring). The device continuously acquires high-fidelity electroencephalography (EEG) signals (e.g., 24-bit resolution at 2 kHz sampling rate per channel) over extended periods of several weeks or months. The "means for performing real-time physiological analysis" is a dedicated ultra-low-power Digital Signal Processor (DSP) optimized for real-time artifact removal, advanced seizure prediction algorithms, and automated sleep stage classification. The power management circuit dynamically adjusts the EEG sampling rate, Analog-to-Digital Converter (ADC) resolution, and DSP processing load based on detected brain states (e.g., quiescent vs. active periods) or predicted event probability, thereby maximizing battery life. The radio communicates highly compressed neural data and event markers via a satellite link (e.g., using Iridium SBD for short-burst data) only when significant neurological events or critical changes in brain state are detected, or on a scheduled weekly summary transmission.

  graph TD
      A[Patient Scalp (EEG)] -- High-Fidelity EEG Signals --> B{Ultra-Low-Power DSP (Real-time Analysis)}
      B -- Analysis Results (Compressed Neural Data, Events) --> C[Power Management Circuit]
      C -- Dynamic Control (Sampling, Resolution, Processing) --> B
      C --> D{Satellite Radio (Iridium SBD)}
      D -- Event/Summary Transmission --> E[Satellite Network]
      E --> F[Neurological Monitoring Platform]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#cfc,stroke:#333,stroke-width:2px,color:#000
      style C fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style D fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style E fill:#cff,stroke:#333,stroke-width:2px,color:#000
      style F fill:#fcc,stroke:#333,stroke:#333,stroke-width:2px,color:#000
  

Derivative 17.3: Cross-Domain Application (Smart Agriculture: Livestock Health Monitoring)

• Enabling Description: This derivative describes a body-worn monitoring device for livestock, non-permanently affixed to an animal's ear or collar. The device integrates accelerometers for continuous activity monitoring (e.g., rumination patterns, gait abnormalities), precise temperature sensors (e.g., thermistor arrays for core body temperature), and non-invasive cortisol sensors (e.g., sweat-based electrochemical sensors). The "means for performing real-time physiological analysis" is a miniature ARM Cortex-M microcontroller executing machine learning-based anomaly detection algorithms to identify early signs of illness, estrus cycles, or distress based on deviations in activity patterns and physiological parameters. The power management circuit employs a sophisticated adaptive duty-cycling scheme, dynamically adjusting the monitoring frequency, sensor activation, and radio transmission intervals based on the animal's activity level and the detected health status. The radio communicates concise status updates and high-priority alerts via a long-range LoRaWAN network to a centralized farm management system, optimizing power consumption for wide-area deployments across large agricultural land.

  graph TD
      A[Animal Body (Ear/Collar)] -- Accel, Temp, Cortisol Sensors --> B{ARM Cortex-M (Anomaly Detection Analysis)}
      B -- Status Updates & Alerts --> C[Power Management Circuit]
      C -- Adaptive Duty-Cycling --> B
      C --> D{LoRaWAN Radio}
      D -- Long-Range Transmission --> E[LoRaWAN Gateway (Farm)]
      E --> F[Farm Management System]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#cfc,stroke:#333,stroke-width:2px,color:#000
      style C fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style D fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style E fill:#cff,stroke:#333,stroke-width:2px,color:#000
      style F fill:#fcc,stroke:#333,stroke:#333,stroke-width:2px,color:#000
  

Derivative 17.4: Integration with Emerging Tech (Reinforcement Learning for Dynamic Power Management)

• Enabling Description: A body-worn patient monitoring device is described featuring a power management circuit significantly enhanced by a reinforcement learning (RL) agent. This RL agent, implemented on a dedicated ultra-low-power AI accelerator (e.g., an FPGA-based inference engine), dynamically optimizes the device's sleep/active cycles, sensor sampling rates, and radio transmission parameters in real-time. The agent learns an optimal policy by observing environmental context (e.g., patient activity levels from accelerometer data, proximity to charging stations via NFC, user interactions), clinical protocols (e.g., higher monitoring intensity during specific hours post-procedure), and anticipating the data's immediate clinical value (e.g., increasing monitoring intensity prior to a statistically predicted cardiac event). The "predetermined event" for communication is dynamically redefined by the RL agent's learned policy, aiming to maximize overall battery life while maintaining or enhancing clinical efficacy. The radio communicates the RL agent's policy decisions and resulting performance metrics alongside the physiological data.

  graph TD
      A[Physiological Signals & Context (Activity, NFC)] --> B{RL Agent (AI Accelerator)}
      B -- Dynamic Optimization Policy --> C[Power Management Circuit]
      C -- Control (Sleep/Active, Sampling, Radio Params) --> D{Sensors & Radio}
      D --> E[Patient]
      D -- Communication --> F[Remote System]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#cfc,stroke:#333,stroke-width:2px,color:#000
      style C fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style D fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style E fill:#cff,stroke:#333,stroke-width:2px,color:#000
      style F fill:#fcc,stroke:#333,stroke:#333,stroke-width:2px,color:#000
  

Derivative 17.5: The "Inverse" or Failure Mode (Graceful Degradation to Minimal Viable Monitoring)

• Enabling Description: A body-worn patient monitoring device is described with a sophisticated graceful degradation strategy for operation under severe power constraints. The power management circuit implements a multi-tier degradation policy. When the primary power source (e.g., rechargeable Li-ion battery) falls below a 5% State of Charge (SoC), the device automatically sheds non-critical functions such as high-resolution graphic displays and advanced computational analysis algorithms. It simultaneously reduces the ECG sampling rate to a bare minimum required for basic heart rate detection (e.g., 50 Hz). If the power further drops (e.g., below 2% SoC), all non-essential hardware (e.g., secondary environmental sensors, Bluetooth radio) is completely powered down. Only an ultra-low-power microcontroller (MCU) with a minimal Low-Dropout (LDO) regulator for a basic pulse oximeter (SpO2) and a sub-GHz RF beacon remain active. This "minimal viable monitoring" mode prioritizes continuous, albeit limited, vital sign data and emergency location signaling for an extended duration (e.g., days), significantly prolonging operational life until patient rescue or device recharge.

  stateDiagram-v2
      [*] --> FullFunctionality: Power > 10%
      FullFunctionality --> DegradedMonitoring: Power 5-10%
      DegradedMonitoring --> MinimalViableMonitoring: Power < 5%
      MinimalViableMonitoring --> CriticalShutdown: Power < 2%
      
      state FullFunctionality {
          HighResDisplay
          AdvancedAnalysis
          FullSamplingRate
          DualRadio
      }
      
      state DegradedMonitoring {
          ReducedDisplay
          BasicAnalysis
          ReducedECGSampling
          SingleRadio
      }
      
      state MinimalViableMonitoring {
          SpO2Only
          BasicHR
          SubGHzBeacon
          UltraLowPowerMCU
      }
      
      state CriticalShutdown {
          DeviceOff
      }
      style FullFunctionality fill:#cfc,stroke:#333,stroke-width:2px,color:#000
      style DegradedMonitoring fill:#ffc,stroke:#333,stroke-width:2px,color:#000
      style MinimalViableMonitoring fill:#fcc,stroke:#333,stroke-width:2px,color:#000
      style CriticalShutdown fill:#ccc,stroke:#333,stroke-width:2px,color:#000
  

---

Derivatives of Independent Claim 18: Body worn patient monitoring device (disposable portion with electrode/power, reusable portion with microprocessor/radio, detachably coupled, non-permanently affixed)

Derivative 18.1: Material & Component Substitution (Biodegradable Electrodes & Magnetic Latching)

• Enabling Description: A body-worn patient monitoring device where the first disposable portion comprises electrodes fabricated from biodegradable conductive polymers (e.g., polylactic acid (PLA) doped with conductive carbon black) directly integrated into a bioresorbable cellulose-based substrate. The power source embedded within this disposable portion is a zinc-air battery, selected for its high energy density and environmental compatibility. The second reusable portion, housing the microprocessor and radio circuit, detachably couples to the disposable portion via an array of biocompatible neodymium magnets embedded in both modules. These magnets provide both robust mechanical securement and ensure reliable conductive electrical contact through spring-loaded pins. The entire device is non-permanently affixed to the patient's body using a hypoallergenic, breathable medical adhesive patch.

  graph TD
      A[Patient Body] -- Biodegradable Electrodes (PLA/C-black) --> B{Disposable Portion (Bioresorbable Cellulose)}
      B -- Zinc-Air Battery --> B
      B -- Magnetic Latching & Spring Pins --> C{Reusable Portion (Microprocessor, Radio)}
      C -- Wireless Communication --> D[Remote Receiver]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style C fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style D fill:#fcc,stroke:#333,stroke-width:2px,color:#000
  

Derivative 18.2: Operational Parameter Expansion (Modular Multi-Parameter Monitoring for Neonates)

• Enabling Description: A body-worn patient monitoring device specifically adapted for neonatal monitoring, featuring a modular, multi-parameter sensing capability. The first disposable portion is a highly miniaturized, ultra-soft, and flexible patch containing multiple micro-electrodes for ECG acquisition, a reflective pulse oximeter sensor, and a high-sensitivity skin temperature thermistor. This patch is engineered for delicate neonatal skin, incorporating a low-tack, repositionable medical adhesive. The integrated power source within this disposable portion is a thin-film solid-state battery. The second reusable portion is a compact, lightweight module that snaps onto the disposable patch via a low-profile, hermaphroditic connector. Its microprocessor performs real-time analysis of neonatal vital signs, including advanced apnea detection and bradycardia alarm algorithms. The radio circuit utilizes a secure, short-range 2.4 GHz medical telemetry protocol to communicate with a bedside monitor or a central nursery station.

  graph TD
      A[Neonatal Skin] -- Micro-ECG, SpO2, Temp Sensors (Ultra-soft Patch) --> B{Disposable Portion (Miniaturized, Thin-Film Battery)}
      B -- Low-profile Hermaphroditic Connector --> C{Reusable Portion (Microprocessor, Radio)}
      C -- Short-Range Telemetry --> D[Bedside Monitor / Nursery Station]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style C fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style D fill:#fcc,stroke:#333,stroke-width:2px,color:#000
  

Derivative 18.3: Cross-Domain Application (Food Quality Sensor for Perishable Goods)

• Enabling Description: This body-worn device is repurposed as a sophisticated food quality sensor for perishable goods. The first disposable portion includes an array of gas sensors (e.g., metal oxide semiconductors for detecting volatile organic compounds indicative of microbial spoilage), electrochemical pH sensors, and precise temperature sensors, all embedded in a thin, flexible polymer film designed for direct adhesion to food packaging or the food item itself. This disposable portion contains a printed flexible battery. The second reusable portion functions as a handheld or fixed-position reader/data logger. It detachably couples to the disposable sensor via a contactless capacitive coupling interface, enabling both data transfer and intermittent power transfer to the disposable unit without physical contact. The reusable portion's microprocessor analyzes the multi-sensor data in real-time to assess food freshness, predict remaining shelf-life, and detect potential spoilage. Results are transmitted via Near Field Communication (NFC) or a local Wi-Fi link to a centralized supply chain management system.

  graph TD
      A[Food Item / Packaging] -- Gas, pH, Temp Sensors (Flexible Film) --> B{Disposable Portion (Printed Flexible Battery)}
      B -- Capacitive Coupling --> C{Reusable Portion (Microprocessor, Radio)}
      C -- NFC / Wi-Fi --> D[Supply Chain Management System]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style C fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style D fill:#fcc,stroke:#333,stroke:#333,stroke-width:2px,color:#000
  

Derivative 18.4: Integration with Emerging Tech (AR-Guided Placement & Digital Twin Synchronization)

• Enabling Description: A body-worn patient monitoring device where the attachment of the first disposable portion to the patient's body is precisely guided by an Augmented Reality (AR) application. This application runs on a smartphone or smart glasses, overlaying dynamic visual cues (e.g., holographic outlines, color-coded zones) directly onto the patient's body to indicate optimal electrode placement for acquiring specific physiological vectors (e.g., Lead I, II, III, or V-leads). Upon successful attachment of the disposable portion and secure coupling of the reusable second portion, the device's physiological data streams are immediately transmitted to update and synchronize a personalized "digital twin" of the patient, hosted in a secure cloud environment. This digital twin provides a dynamic, predictive computational model of the patient's health, continuously integrating real-time data for advanced simulations, personalized treatment recommendations, and proactive health management. The radio circuit communicates with the AR guidance device (via Bluetooth Low Energy) and continuously uploads encrypted data to the digital twin platform (via Wi-Fi or cellular network).

  graph TD
      A[Patient Body] -- AR Visual Cues (Smartphone/Smart Glasses) --> B{Disposable Portion (Electrode)}
      B -- Adhesion & Coupling --> C{Reusable Portion (Microprocessor, Radio)}
      C -- Bluetooth --> D[AR Device (Smartphone/Smart Glasses)]
      C -- Wi-Fi/Cellular --> E[Secure Cloud (Digital Twin Platform)]
      E --> F[Predictive Health Model / Treatment Recs]
      style A fill:#fff,stroke:#333,stroke-width:2px,color:#000
      style B fill:#f9f,stroke:#333,stroke-width:2px,color:#000
      style C fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style D fill:#cff,stroke:#333,stroke-width:2px,color:#000
      style E fill:#fcc,stroke:#333,stroke:#333,stroke-width:2px,color:#000
      style F fill:#cfc,stroke:#333,stroke:#333,stroke-width:2px,color:#000
  

Derivative 18.5: The "Inverse" or Failure Mode (RFID-Enabled Disposable Module Verification & Self-Deactivation)

• Enabling Description: A body-worn patient monitoring device is disclosed, incorporating a first disposable portion with an embedded passive RFID tag. This RFID tag is pre-programmed at manufacturing with critical metadata about the disposable module, including its unique serial number, manufacturing date, expiry date, and a "single-use" flag. When the reusable second portion is coupled, its microprocessor initiates an RFID scan to perform a multi-factor verification of the disposable module. This verification process checks for authenticity, expiry status, and confirms that the "single-use" flag has not been previously activated. If the disposable module is determined to be expired, unauthentic, or if the "single-use" flag indicates prior usage, the reusable portion activates an internal self-deactivation circuit within the disposable module. This is achieved, for example, by sending a controlled high-current pulse through a dedicated fusible link on the disposable module's circuit, rendering the electrodes permanently non-functional. This mechanism prevents unintended reuse, ensures patient safety by mandating fresh components, and maintains the integrity of collected data.

  sequenceDiagram
      participant R as Reusable Portion
      participant D as Disposable Portion (with RFID)
      R->>D: RFID Scan (Query Metadata)
      Note over D: RFID Tag responds with Serial #, Expiry, Usage Flag
      R->>R: Microprocessor Verifies Metadata
      alt Invalid/Expired/Used Disposable
          R->>D: Send Deactivation Command (High-Current Pulse)
          Note over D: Fusible Link Activated, Electrodes Non-Functional
          D--xR: Disposable Module Deactivated
          R->>R: Log Deactivation Event
      else Valid Disposable
          R->>D: Activate Monitoring
          R->>D: Power Transfer
          R->>R: Start Patient Monitoring
      end
      style R fill:#ccf,stroke:#333,stroke-width:2px,color:#000
      style D fill:#f9f,stroke:#333,stroke-width:2px,color:#000
  

---

Combination Prior Art Scenarios

The following scenarios describe combinations of US Patent 8630699's teachings with existing open-source standards, thereby establishing prior art for integrations that might otherwise be claimed as novel.

1. Combination of US8630699 (Claim 1: Body Worn Device with Radio & Analysis) with HL7 FHIR Standard (ISO 21707:2023):

   • Description: The "radio circuit to communicate a raw physiological signal or a result of the physiological analysis...via a radio transmission to a remote radio receiver" as described in Claim 1 of US8630699, when implemented to transmit data conforming to the Health Level Seven (HL7) Fast Healthcare Interoperability Resources (FHIR) standard (ISO 21707:2023). Specifically, the physiological analysis results (e.g., ECG interpretations, derived heart rates, arrhythmia alarms, and other vital signs) would be structured as FHIR Observations or DiagnosticReports resources. This structuring would facilitate seamless and standardized integration into Electronic Health Record (EHR) systems and ensure interoperability with various other healthcare applications. The body-worn device would implement FHIR profiles relevant to vital signs and cardiovascular observations, transmitting these as JSON or XML payloads over standard network protocols such as HTTP(S) over Wi-Fi, or MQTT over cellular networks. This combination renders obvious any subsequent patent claims attempting to integrate body-worn physiological monitors with standardized healthcare data exchange protocols using FHIR.

   graph TD
       A[US8630699 Body Worn Device] --> B{Radio Circuit (Claim 1)}
       B -- Transmits FHIR Observations/DiagnosticReports --> C[HL7 FHIR Standard (ISO 21707:2023)]
       C --> D[EHR System / Healthcare Application]
       style A fill:#cfc,stroke:#333,stroke-width:2px,color:#000
       style B fill:#cff,stroke:#333,stroke-width:2px,color:#000
       style C fill:#f9f,stroke:#333,stroke-width:2px,color:#000
       style D fill:#fcc,stroke:#333,stroke-width:2px,color:#000
   

2. Combination of US8630699 (Claim 17: Power Management & Radio) with MQTT Protocol (ISO/IEC 20922:2016):

   • Description: The "power management circuit for reducing power consumption of said device by entering a sleep mode during periods of non-useful physiological data acquisition and exiting said sleep mode to actively monitor the patient and perform said analysis" and the "radio for communicating results of said analysis" as detailed in Claim 17 of US8630699, where the radio communication utilizes the Message Queuing Telemetry Transport (MQTT) protocol (ISO/IEC 20922:2016). The device's microprocessor, upon exiting sleep mode, publishes physiological data (e.g., heart rate, alarm states, device battery status, and activity levels) as small, lightweight MQTT messages to a remote MQTT broker. This publish/subscribe model, combined with MQTT's Quality of Service (QoS) levels (e.g., QoS 0 for non-critical, periodic data; QoS 1 for critical alarms), significantly optimizes energy consumption by minimizing data overhead and connection time to the network, aligning perfectly with the patent's explicit goal of power reduction. This combination would make obvious the use of MQTT for efficient, event-driven, and power-optimized data transmission from body-worn physiological monitors, especially in IoT contexts.

   graph TD
       A[US8630699 Body Worn Device] --> B{Power Management Circuit (Claim 17)}
       B -- Exits Sleep Mode --> C{Microprocessor / Radio}
       C -- Publishes Lightweight MQTT Messages --> D[MQTT Protocol (ISO/IEC 20922:2016)]
       D --> E[Remote MQTT Broker]
       E --> F[Subscribing Healthcare / Monitoring System]
       style A fill:#cfc,stroke:#333,stroke-width:2px,color:#000
       style B fill:#cff,stroke:#333,stroke-width:2px,color:#000
       style C fill:#f9f,stroke:#333,stroke-width:2px,color:#000
       style D fill:#ccf,stroke:#333,stroke-width:2px,color:#000
       style E fill:#fcc,stroke:#333,stroke-width:2px,color:#000
       style F fill:#cfc,stroke:#333,stroke-width:2px,color:#000
   

3. Combination of US8630699 (Claim 12: Printed Circuit Protection) with IPC-2221 Standard (Generic Standard on Printed Board Design):

   • Description: The method of "printing the first material... and printing the second material... wherein at least part of the second material overlays the first material" for high-voltage circuit protection, as taught in Claim 12 of US8630699, when designed and manufactured in accordance with the IPC-2221 Generic Standard on Printed Board Design. Specifically, the determination of print patterns, thicknesses, and spacing for both the resistive and conductive materials on the substrate would adhere to the minimum conductor spacing requirements, dielectric material specifications (e.g., regarding dielectric strength and insulation resistance), and thermal management considerations (e.g., trace width for current carrying capacity and heat dissipation) outlined in IPC-2221. This adherence ensures reliable operation, manufacturability, and safety under defibrillation voltages. This combination renders obvious any claims that apply established industry standards for printed circuit board design, particularly concerning material deposition and trace geometries for safety-critical high-voltage applications, to the manufacturing of integrated resistive protection elements.

   graph TD
       A[US8630699 Method (Claim 12)] --> B{Determine Print Patterns & Thicknesses}
       B -- Apply IPC-2221 Guidelines (Spacing, Materials, Thermal) --> C[Print First Resistive Material]
       C --> D[Print Second Conductive Material (Overlay)]
       D --> E[Manufacture High-Voltage Protected Substrate]
       style A fill:#cfc,stroke:#333,stroke-width:2px,color:#000
       style B fill:#cff,stroke:#333,stroke-width:2px,color:#000
       style C fill:#f9f,stroke:#333,stroke-width:2px,color:#000
       style D fill:#ccf,stroke:#333,stroke-width:2px,color:#000
       style E fill:#fcc,stroke:#333,stroke-width:2px,color:#000